A review of clinical trial results revealed that patients with non-metastatic prostate cancer receiving androgen deprivation therapy (ADT) can benefit from osteoporosis therapies, known as bisphosphonates, and from Prolia (denosumab), which significantly increase bone mineral density (BMD). The review, “Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer,” was published in the journal Annals of Internal Medicine. ADT is the most common therapy used in men diagnosed with prostate cancer. But the therapy “is associated with many potential adverse effects, including significant bone loss and increased risk for low trauma or fragility fractures similar to that in persons with primary osteoporosis,” researchers wrote. The new study by researchers at the University to Toronto found that non-metastatic prostate cancer patients starting or continuing ADT had significantly less BMD loss when they were given bisphosphonates (a class of medicines that slow down or prevent bone loss) and Prolia (the only FDA-approved therapy for cancer treatment-induced bone loss), compared with those receiving a placebo, normal care, or other active treatments.